|
Status |
Public on Feb 13, 2019 |
Title |
Local administration of IFN-α-iPSC-pMCs alters gene expression profiles in tumor microenvironment. |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Local administration of IFN-α-producing proliferating myeloid cells (IFN-α-iPSC-pMCs) inhibited the tumor growth not only at the treatment site (right) but also at the distant site (left). We identified genes with log fold expression change ≥ 1 or ≤ −1 in untreated versus IFN-α-iPSC-pMC-treated tumors and iPSC-pMC-treated versus IFN-α-iPSC-pMC-treated tumors for treatment or distant site, respectively. Of the overlapping genes differentially expressed in IFN-α-iPSC-pMC-treated mice, 301/671 distant site and 460/928 treated site genes were ISGs, of which 95.3% and 94.7%, respectively, were type I IFN-related. By gene ontology, the up-regulated ISG signatures were enriched for “T cell-mediated immune responses”, “cytolysis”, and “migration of immune cells” associated genes. Collectively, Local administration of IFN-α-iPSC-pMCs alters the tumor microenvironment and propagates molecular signature associated with type I IFN.
|
|
|
Overall design |
Gene expression profiles of treated tumor (right) and distant tumor (left)
|
|
|
Contributor(s) |
Uemura Y, Zhang R |
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Feb 08, 2019 |
Last update date |
Mar 21, 2019 |
Contact name |
Ranmaru Shimoda |
E-mail(s) |
shimoda@rhelixa.com
|
Phone |
+818043368250
|
Organization name |
Rhelixa, Inc.
|
Street address |
3F Yayoi Bldg., 3-7-4 Iwamotocho
|
City |
Chiyoda |
State/province |
Tokyo |
ZIP/Postal code |
101-0032 |
Country |
Japan |
|
|
Platforms (1) |
GPL17021 |
Illumina HiSeq 2500 (Mus musculus) |
|
Samples (18)
|
|
This SubSeries is part of SuperSeries: |
GSE126281 |
Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells |
|
Relations |
BioProject |
PRJNA521845 |
SRA |
SRP185726 |